Daewoong Eyes Entry Into China Stem Cell Sector
This article was originally published in PharmAsia News
After a licensing deal with stem cell company Kang Stem Biotech a few months ago, Daewoong Pharm is now accelerating its efforts to expand in the sector internationally through a deal for the Chinese market. To tackle difficulties faced by foreign pharma firms in gaining regulatory approvals in China, the two South Korean companies will involve the Chinese government in the project.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.